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Pertussis toxin (PT), 1 a protein released by Bordetella pertussis organisms, is a major
virulencefactor in whooping cough (1) . Awide varietyof biological effectshave been
attributed to thetoxin, which includelymphocytosis, histamine release, insulin secre-
tion, stimulation ofIgE production, and adjuvanticity (2-4) . AnmAb to PT pro-
tects mice challenged intracerebrally (i.c .) with virulent B. pertussis (5) . A toxoided
PT was therefore selected to be one of the two main component of an acellular
whooping cough vaccine, now in clinical trials (6) . However, the toxin is thought
to be responsible for the harmful side effects associated with the current vaccine .
There is speculation that active toxin present in whole cell vaccine, and perhaps
chemically toxoided PT in acellular vaccine, may cause rare but serious reactions
including a state of hypotonia and hyporesponsiveness, convulsions, and encepha-
lopathy (7, 8) .
The genes coding for the five subunits of PT have been cloned and sequenced
(9, 10) . It was proposed that it may be possible to develop a safe but nonreactogenic
vaccine by genetic manipulation of the toxin gene . We have recently demonstrated
that site-specificmutants ofthe S1 subunit ofPT were deficient in pathogenic activi-
ties associated with B . pertussis including leucocytosis, potentiation ofa shock-like
state with convulsions, and stimulation of histamine sensitivity and adjuvanticity
(11) . However, genetic constructs ofPT with an insertion or deletion of a site from
residues 140-142 in the Sl subunit, the probable active ADP-ribosylase site, were
reduced in their protective capacity in the i.c . challenge test in mice (11) . We have
investigated whether the immune response to the S1 subunit in man is directed to
sites distinct from the ADP-ribosylation locus .
T lymphocytes recognize fragments ofnative immunogen, termed epitopes, phys-
ically bound to elements ofMHC proteins . The empirical analysis of peptide epi-
topes that were recognized by T cells reveals that they share several common fea-
tures . Accordingly, a number of investigators proposed different models to predict
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the immunodominant epitopes of an antigen . DeLisi and Berzofsky postulated that
helper T cells preferentially recognize amphipathic helices (12). Rather than con-
sider secondary structure, Rothbard and his collegues observed that a large percentage
of antigenic sites contain a linear pattern composed of a charged residue or a glycine
followed by two hydrophobic residues (13) . We have recently used the Rothbard
algorithms to detect the encephalitogenic domains of myelin basic protein causing
autoimmune encephalomyelitis in mice (14), and the immunogenic domains of ace-
tylcholine receptor in patients with myasthenia gravis (15) . Synthetic peptides corre-
sponding to chosen epitopes are capable of eliciting a specific immune response to
the intact native protein . Consequently, it is feasible to use synthetic peptide vac-
cines to induce protective immunity against infections by microorganisms . In the
present work we use two alogrithms to predict antigenic sites in the Sl subunit of
the PT molecule, and analyze the HLA restriction elements in the response patterns .
Materials and Methods
Synthetic Peptides.
￿
Peptides were synthesized by solid-phase technique (16) on a peptide
synthesizer fabricated at SRI International (Menlo Park, CA), starting with commercially
available t-Boc amino acid polystyrene resin and t-Boc protected amino acids with the fol-
lowing side-chain protecting groups : O-benzyl esters for Asp and Glu, O-benzyl ethers for
Ser and Thr, tosyl for Arg and His, p-methoxybenzyl for Cys, ortochlorobenzyloxycarbonyl
for Lys, and 2,6-dichlorobenzyl for Tyr. All couplings were performed using 2.5 molar excess
oft-Boc amino acid and dicyclohexyldocarbodiimide (DCC) over the number of milliequiva-
lents of amino acid on the resin. In the case of Asn and Gln, a 2 .5 molar excess ofN-hydroxy-
benzotriazole (HOBT) was added . If the peptides had His in their sequence, then for Asn
and Gln, active ester (p-nitrophenyl) couplings were performed . All the couplings were moni-
tored by the ninhydrin test . 40% TFA/dichloromethane containing 0.1% indole was used
for Boc deprotection . After synthesis, the peptides were cleaved from the resin using anhy-
drous hydrofluoric acid (HF) in HFReaction Apparatus Type II (Peninsula Laboratories,
Inc ., Belmont, CA) . The peptides were separated from the various organic side products by
extraction with ether and isolated from the resin by extraction with 50% acetic acid, diluted,
and lyophilized . Crude peptides were purified by gel filtration on Sephadex LH-20 . Purity
of the peptides was checked by analytical reverse-phase HPLC and amino acid analysis.
Subjects .
￿
PBL of healthy adult volunteers previously immunized with the whole cell B.
pertussis vaccine were isolated by centrifugation over Histopaque gradients (Sigma Chemical
Co., St . Louis, MO) . HLA-DR, DQ typing was performed on nylon-wool T cell-depleted,
B cell-enriched lymphocytes by the National Institutes of Health standard complement-
dependent extended microcytotoxicity technique.
Proliferation Assay.
￿
PBL from HLA-DR, DQ typed donors were cultured with different
concentrations of the synthetic peptides in round-bottomed microtiter plates at a concentra-
tion of 2 x 10 5 cells in 0.2 ml of culture medium . Culture medium was composed ofRPMI
1640 (Mediatech, Washington, DC) supplemented with 20% heat-inactivated pooledhuman
serum (Irvine Scientific, Santa Ana, CA), 2 HIM L-glutamine, and antibiotics . After 72 h,
cultures were pulsed with [3H]thymidine (1 mCi/well, sp act 5 Ci/mM) . 18 h later the cells
were harvested and thymidine incorporation was measured in a liquid scintillation counter.
Preparation of APCs and T Lymphocytes.
￿
APCs were prepared from PBL as described by
Freundlich and Avdalovic (17) . Briefly, the method involves the incubation for 120 min and
adherence ofcells bearing receptors for fibronectin to plastic petri dishes coated with gelatin
and autologous plasma . An enriched T lymphocyte population was obtained by passage of
the fibronectin-nonadherent cells through a nylon wool column . Using a panel ofmAbs we
were able to show that the fibronectin adherent cells are positive for HLA class I and class
II antigens and do not express T cell markers (18) .
Antibody Blocking Experiments .
￿
Fibronectin adherent APCs or nonadherent T cells were
incubated for 60 min with various concentrations of the different mAbs . Cells were exten-OKSENBERG ET AL.
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sively washed before coculture. Blocking was determined by the percent of the response ob-
tained in the presence ofantigen plus mAb, divided by the response with antigen alone. The
following mAbs were used: L243, an anti-HLA-DR (mouse IgG2a) reactive with a mono-
morphic HLA-DR epitope; SK10, an anti-HLA-DQ (Leu-10) (mouse IgGl), which recog-
nizes a common polymorphic epitope on DQw 1 and DQw 3 molecules; B7/21, an anti-
HLA-DP (mouse IgGI), which recognizes a monomorphic epitope present on DP molecules
ofcells expressing DPI, DP2, DP3, DP4, or DP5; and anti-CD4 (Leu-3a) (Becton Dickinson
& Co., Mountain View, CA). Polyclonal rabbit anti-PT was obtained by consecutive injec-
tion of PT (islet-activating protein; List Biological Laboratories, Campbell, CA) in CFA.
Rabbits were injected intramuscularly with 3 ml of the emulsified antigen (200 ng/ml). Im-
munization was repeated after 1 mo, and rabbits were bled 2 wk later. Boosting and bleeding
cycle was repeated after a 3-wk resting period.
Bromodeoxyuridine andLight Treatment.
￿
Responder lymphocytes (10'/flask) and X-irradiated
stimulator lymphocytes (10'/flask) were cocultured at 37°C, 5% C02 in 20 ml of culture
medium. 2 mg/ml of 5-bromo-2'-deoxyuridine (Brd Urd; Sigma Chemical Co.) were added
to the cultures at 48 h. At 72 h the cultures were illuminated for 180 min by a fluorescent
light source to eliminate alloreactive clones (19). This procedure diminished the specific al-
logeneic response by -75-85%. The surviving clones were then incubated with peptide primed
APC to test genetic restriction. It should be noted that the ability of these cells to respond
to PHA and nonrelevant allogeneic stimulation was not compromised by the treatment.
Results
T cells recognize linear sequences of8-12 amino acidswithin native protein mole-
cules. The peptide fragments are bound to HLA molecules, and the T cell recog-
nizes the peptide plus HLA in a three-body interaction. Two predictive templates
were used to generate potential T cell epitopes of PT One algorithm used criteria
for predicting regions that would react with antibody (20). Those linear peptides
most likely to elicit B cell responses are in regions of high flexibility. T cell epitopes
are frequently near the B cell sites (21, 22). These regions include the NH2-terminal
portion of the protein and regions of predicted 0 turns (23, 24) (residues 44-54,
64-75, 87-98, 104-116, and 206-218). Thus, use of this algorithm might predict some
potential T cell epitopes that overlap B cell epitopes. The second method for predicting
T cell epitopes involves sequences with a charged amino acid or glycine, followed
by two or three hydrophobic amino acids, and then a polar amino acid or glycine
(13) (residues 133-146, 151-161, 169-179, 180-190, 223-233).
Based on the above criteria the peptides detailed in Table I were synthesized. Healthy
Residues
44-54
64-75
87-98
104-116
206-218
133-146
151-161
169-179
180-190
223-233
TABLE I
PT (Subunit 1) Peptides Used for T Cell Stimulation
Peptide
NH2-Arg-Tyr-Asp-Ser-Arg-Pro-Pro-Glu-Asp-Val-Phe-000H
NH2-Asp-Asn-Val-Leu-Asp-His-Leu-Thr-Gly-Arg-Ser-Cys-COOH
NH2-Thr-Ser-Ser-Ser-Arg-Arg-Tyr-Thr-Glu-Val-Tyr-Leu-COOH
NH2-Glu-Ala-Val-Glu-Ala-Glu-Arg-Ala-Gly-Arg-Gly-Thr-Gly-COOH
NH2-Arg-Ala-Asn-Pro-Asn-Pro-Tyr-Thr-Ser-Arg-Arg-Ser-Val-COOH
NH2-Gly-Ala-Ala-Ser-Ser-Tyr-Phe-Glu-Tyr-Val-Asp-Thr-Tyr-Gly-COOH
NH2-Arg-Ile-Leu-Ala-Gly-Ala-Leu-Ala-Thr-Tyr-Gln-COON
NH2-Arg-Ile-Pro-Pro-Glu-Asn-Ile-Arg-Arg-Val-Thr-COOH
NH2-Arg-Val-Tyr-His-Asn-Gly-Ile-Thr-Gly-Glu-Thr-COOH
NH2-Gly-Thr-Leu-Val-Arg-Met-Ala-Pro-Val-Ile-Gly-COOH1858
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adult volunteers previously immunized with B . pertussis vaccine as children were tested .
It was of interest to determine the efficiency of the two different algorithms used
to predict the immunogens . Fig. 1 illustrates a representative dose-response experi-
ment in which PBL ofdonorJO (HLA-DR 3,8 ; DQw 2) responded to 3 of the 5
peptides selected by the first algorithm (Fig. 1 A), and to 2 of the 5 peptides that
were selected by the Rothbard rules (Fig. 1 B) . It should be noted that p64-75 (Fig.
1 A) includes a charged, hydrophobic, hydrophobic, glycine amino acid sequence
(MLTG) . The efficiency of the two methods is relatively similar and demonstrates
the complex immunological properties of the PT molecule .
Individual responses to various peptides differed markedly (Fig . 2) . Each individual
could be stimulated by more than one peptide, but none of the peptides elicited a
response in the entire panel of responders . However, it was possible to show that
by simultaneous stimulation with the combination of two peptides, p64-75 and
p151-161, it is possible to cover the entire responder panel.
For a peptide to be considered as a putative vaccine, homology with other an-
tigens, including self antigens, must be considered (25) . In a computerized search
for similarities with other published protein sequences, homology was found be-
tween p151-161 and DNA-directed RNA polymerase and gas vesicle protein of
Calothrix species :
DNA-directed RNA polymerase 602-DILS I PLV IYQ
PT
￿
151-RILAGALATYQ
Gas vesicle protein
￿
44-RIV IASVETYL
FIGURE 1 .
￿
Dose-response toPT peptides chosen
according to the (A) algorithm for high antigenic
index, or (B) by a sequence described by Roth-
bard and Taylor (13) (B). Each point represents
the mean of three different triplicate determina-
tions, and SD values never exceeded the 15% of
the mean cpm .OKSENBERG ET AL.
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FIGURE 2 .
￿
Lymphocyte proliferation in-
dices from nine normal HLA-DR typed
individuals to thePT peptides at 2, 5, 10,
20, and 100 gg/ml . Results are given for
the peptide concentration that elicited the
greatest proliferation, which was usually
10 or 20 gg/ml. Backgroundcpm (no pep-
tide) ranged from 150 to 2,500 cpm . High
responders are indicated as (90, SI> 15) ;
intermediate responders (®, SI > 6 and
< 15); low responders (®, SI > 3 and< 6) ;
no responders (p, SI < 3) .
Because individuals who share HLA genotypes would not be expected to share
TCR genotypes since they segregate on different chromosomes, it is not surprising
that even individuals sharing HLA types might differ in their response to specific
peptides (26). We noted, for example, that individuals sharing the HLA-DR 2,5
genotype both responded to p44-54 and p133-146, but did notboth respond to sev-
eral other peptides, p64-75, p87-98, p151-161, p169-179, and p223-233 (Fig. 2). To
analyze the role ofHLA molecules in response to PT peptideswe used two different
approaches : blockade of the response to agiven peptidewith mAb directed toHLA-
D molecules and useofHLA-D matchedAPC forpresentation ofpeptides to heter-
ologous purifiedT cells . As shown in Fig. 3, with three different individuals, presen-
tation of peptides 44-54, 104-116, 206-218, 133-146, 151-161, and 223-233 by
fibronectin-adherent APC was largely inhibited by the anti-HLA-DR mAb, while
anti-HLA-DQwas only able to suppress certain responsesby-10-20% . Leu-10 mAb
(anti-HLA-DQwl,w3) blocked the responses to peptides 64-75, 87-98, and 169-179,
FIGURE 3 .
￿
Antibody blocking of PT peptide presentation to three different individuals . The
response without antibody is indicated as (/) . Fibronectin-adherent APC were treated with anti-
HLA-DR (E), anti-HLA-DQ(®), or anti-HLA-DP(®), at a final concentration of 1 :100 . Bars
representmean cpmoftwo different triplicate determinations, and SD values never exceded the
15% of the mean cpm.1860
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while the anti-HLA-DRmAb was associated with a much smaller reduction in the
response to these peptides . Treatment ofAPC with anti-HLA-DP or control rabbit
anti-PT antibodies caused only marginal reductions in the responses . It appearsfrom
these results that different epitopes of the PT molecule associate with either HLA-
DR orDQ determinants . Our antibody blocking studies showed also that peptide
stimulation could be blocked by treatment of nonadherent responder lymphocytes
with anti-CD4 but not anti-HLA class II mAb (Fig. 4) .
The second experimental approach involved use ofheterologousAPC andTcells,
which differ or share HLA-DR,DQ determinants . Alloreactive T cell clones were
inactivated by Brd Urd and light treatment, which eliminated irrelevant prolifera-
tive reactions . As shown in Table II, only combinations in which the APC shared
HLA-class II antigens with the responderT cells resulted in significant peptide re-
sponses . Analyses of Table II and Fig . 2 reveals the possible role of theT cell reper-
toire in thepeptide response . Combinations of a nonresponderAPC and responder
T cells gave positive responses, while responder APC andnonresponderTcells yielded
negative responses . For example, HLA-DR 2,4 ; DQwl,w3APC effectivelypresented
p104-116, p133-146, p151-161, p169-179, and p223-233 to HLA-DR 1,4; DQwl,w3
T cells . The individual whowasHLA-DR 2,4; DQw1,w3 responded to p87-98 and
p169-179 as well as to p104-116, p133-146, p151-161, and p223-233 (Fig . 2), but the
HLA-DR 2,4; DQwl,w3 APC could not effectively present p87-98 or p169-179 to
theTcells oftheHLA-DR 1,4; DQw1,w3 individual, who isanonresponder to these
peptides. A similar pattern was seen with HLA-DR 5,7 APC and HLA-DR w6,7
T cells, where responses were effectively mounted to p44-54, p133-146, p151-161,
andp223-233, but not to p64-74 and p104-116, which effectively stimulated the donor
of the APC, but not the donor of the T cells . To demonstrate further the role of
T cell phenotype in the response to various pertussis peptides we also examinedHLA-
DR 2,5 T lymphocytes with HLA-DR 5,7APC . The HLA-DR 2,5 individual did
not respond to p104-116, but did respond to 44-54, 133-146, and 151-161 . Thus, the
failure ofDR 5,7 APC to present p104-116 to DR w6,7 T cells is not due to the
lack of complete class II MHC matching .
Discussion
There is serious concern about the potential reactogenicity ofB . pertussis vaccine .
TheDPT vaccine is associated with convulsions in 1 of 1,750 doses, and permanent
neurologic damage occurs in 1 of every 310,000 doses (7, 27) . In response to pub-
FIGURE 4 .
￿
Antibody blocking ofT cell proliferative re-
sponses to 10 mg/ml ofPT peptide 151-161 . Fibronectin
nonadherent lymphocytes were treated with anti-CD4
(®), anti-HLA-DR(®), anti-HLA-DQ(®), or anti-
HLA-DP (9), at a final concentration of 1 :100 .OKSENBERG ET AL .
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TABLE II
MHC Restriction and T Cell Reactivity after Brd Urd and Light Treatment
T cells
Purified T lymphocytes after Brd Urd and light treatment subsequently stimulated with peptide-primed
heterologous APC .
t Each value represents the mean of two different triplicate determinations . Standard deviation values never
exceeded the 127o of mean cpm .
§ Stimulation Index (SI) = (Experimental cpm + antigen)/(Control cpm - antigen).
II Responses SI >3 are underlined .
licity concerning these potential hazards of pertussis vaccines, vaccination accep-
tance fell to a level below 50% in Britain in the mid-1970s (28). There is interest,
therefore, in developing a safer DPT vaccine.
The use ofsynthetic peptides as vaccines is currently being explored foranumber
of infectious diseases, including malaria, hepatitis B, and AIDS (29) . One hazard
of vaccines based particulary on discrete peptides may be the variability in the re-
sponse among different individuals with different HLA types . In the present work
weexamined the MHC-restricted Tcell responses to synthetic peptides corresponding
to the subunit I of the pertussis toxin sequence . Of the 10 peptides, 9 elicited vig-
orous responses as detected by cellular proliferation and [3H]thymidine uptake. It
was important however, to identify a family of peptides derived from the pathogen
thatwould be immunogenic for all the individuals to be vaccinated . A combination
of two partially immunostimulatory peptides resulted in complete coverage forT
cell responses for all the individuals in our panel . When broader groups are tested,
itmaybe possible to achievewide or complete coverage with arelatively small number
of peptides .
TheT cell response to various antigens has been shown to be restricted to certain
HLA-DR, DQ, orDP types. Several examples demonstrate the associationbetween
specific HLA types and the immune response to viral (30), bacterial (31), parasitic
(32), and even synthetic antigens. An example ofsuch a correlation wasrecently pro-
vided by Brocke and colleagues (15), whodemonstrated that the antigens HLA-DR 5
andDR 3 are differentially associated with proliferative responses to distinct pep-
tides of theacetylcholine receptor molecule in myasthenia gravis patients . We there-
fore used different anti-class II mAbs to determine the contribution ofthe different
APC HLA-DR 2,4 ; DQ wl,w3 APC HLA DR 5,7 ; DQ w2,w3
HLA-DR 1,4 HLA-DR 3,w8 HLA-DR w6,7 HLA-DR 2,5 HLA-DR1,-
T cells' DQ wl,w3 DQ w2 DQ wl,w3 DQ wl,w3 DQ wl
Peptides cpm (SI) cpm (SI)
44-54 1,2601(0.95)§ 1,670 (1 .05) 12,830 (4.48) 7,830 (8 .20) 2,910 (1 .71)
64-75 1,230 (1 .04) 2,560 (0.67) 725 (0.69) 1,230 (1.50) 3,860 (1 .54)
87-98 1,920 (0.83) 1,880 (1 .89) 854 (0.64) 960 (0.55) 1,910 (1 .59)
104-116 16,730 (5.46) 2,960 (1 .27) 710 (1 .01) 2,110 (2 .34) 660 (0.67)
206-218 1,870 (1 .80) 2,490 (1 .74) 530 (0.47) 1,530 (1 .20) 960 (1 .77)
133-146 31,125 (12.20) 860 (0.77) 24,860 (8.63) 3,765 (3 .44) 3,820 (2.74)
151-161 9,920 (11 .40) 1,780 (0.89) 25,330 (8.40) 7,810 (6.35) 4,190 (1 .63)
169-179 4,010 (5.07) 2,280 (1 .78) 830 (0.77) 1,960 (2.20) 750 (0.96)
180-190 1,210 (1.07) 1,975 (2.29) 1,930 (1 .94) 2,210 (1 .85) 920 (0.87)
223-233 22,860 (11 .72) 3,320 (1 .44) 48,960 (13.19) 2,810 (2 .20) 1,970 (1 .28)1862
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HLA class II molecules in theT cell response to PT peptides . It appears that it is
possible to characterize responses to different peptides withsome responses associated
with HLA-DR, and some with HLA-DQMHC determinants . Associations such
as these could be due to the selective physical association of these peptides with a
particular class II antigenic site (33, 34) .
Using Brd Urd and light treatment to block proliferation due to alloreactivity,
we demonstrated the requirement for at least partial genetic identity at the MHC
class II level betweenAPC and responderT lymphocytes . Interestingly, Tcells from
nonresponder donors for a particular epitope fail to respond to the relevant peptide
even in the presence ofhistocompatible APC from a responder donor, andconversely,
Tcells from a responder donor will respond to the peptide in the presence ofhistocom-
patibleAPC from a nonresponder donor. These data clearly show the importance
of the T cell genotype in the specificity of the response .
The association of the ADP-ribosyl transferase activity of PT with the im-
munomodulatory properties of B . pertussis suggested that ADP-ribosylase activity
is necessary for optimal immunoprotection (11) . The present data indicate that pep-
tides of the Sl subunit ofPT containing stretches distinct from Glu 140, a critical
component of the ADP-ribosylase enzymatic site, are immunogenic in man . A re-
cent study describes other peptides of the Sl subunit of PT, again distinct from Glu
140, that bind antisera from infants immunized with B . pertussis (35) . Thus in man,
optimal immunoprotection may notnecessarily require animmune response to epi-
topes of PT including Glu 140 in the S1 subunit.
These results indicate that it might indeed be possible to construct a vaccine with
a limited number of PT peptides that could cover a wide population . This raises
an important issue. Potency testing forB . pertussis vaccine uses the intracerebral chal-
lenge test in CFW outbred mice (36, 37) . This test has not proven useful for testing
acellular B . pertussis vaccines or for peptides (38) . We plan to see whether the pep-
tides that elicit HLA-restricted T cell responses in man do indeed protect in the
intracerebral challenge test, as well as ascertain whether these peptides block other
PT reactions including lymphocytosis . If these peptides can evoke protective T and
B cell responses in such assays, then it might be possible and acceptable to consider
them as a candidate vaccine .
Summary
The Sl subunit of Pertussis toxin (PT) is responsible for the reactogenicity and
in part the immunogenicity of Bordetella pertussis vaccine . The critical residues as-
sociated with the immunomodulatory effects ofPT were located around Glu14o in
the Sl subunit . In man, T cell responses to PT are directed at Sl peptides distinct
from Glu 14o . Two such epitopes, p64-75 and p151-161, are immunogenic in a panel
of individuals covering a wide range ofHLA genotypes . The response to PT pep-
tides isHLA class II restricted . The response top64-75 is blocked by an anti-HLA-
DQmAb, while that to p151-161 is blockedby an anti-HLA-DR mAb. These findings
may allow for the development of a B . pertussis vaccine free from reactogenicity.
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